Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Corrigendum to "Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations" [Spectrochim. Acta A Mol. Biomol. Spectrosc. 174 (2017) 326-330].

El-Bagary RI, Elkady EF, Farid NA, Youssef NF.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:23. doi: 10.1016/j.saa.2017.02.044. Epub 2017 Mar 16. No abstract available.

PMID:
28315823
2.

Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations.

El-Bagary RI, Elkady EF, Farid NA, Youssef NF.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Mar 5;174:326-330. doi: 10.1016/j.saa.2016.11.048. Epub 2016 Dec 3. Erratum in: Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:23.

PMID:
27984753
3.

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

Kelly RP, Close SL, Farid NA, Winters KJ, Shen L, Natanegara F, Jakubowski JA, Ho M, Walker JR, Small DS.

Br J Clin Pharmacol. 2012 Jan;73(1):93-105. doi: 10.1111/j.1365-2125.2011.04049.x.

4.

Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE.

Clin Pharmacokinet. 2010 Dec;49(12):777-98. doi: 10.2165/11537820-000000000-00000. Review.

PMID:
21053990
5.

Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.

Small DS, Li YG, Ernest CS 2nd, April JH, Farid NA, Payne CD, Winters KJ, Rohatagi S, Ni L.

J Clin Pharmacol. 2011 Mar;51(3):321-32. doi: 10.1177/0091270010367429. Epub 2010 Apr 21.

PMID:
20410452
6.

Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2010 Jun;38(6):898-904. doi: 10.1124/dmd.110.032086. Epub 2010 Mar 12.

PMID:
20228231
7.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.

Clin Ther. 2010 Feb;32(2):365-79. doi: 10.1016/j.clinthera.2010.02.015.

PMID:
20206794
8.

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

Farid NA, Kurihara A, Wrighton SA.

J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. Review. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483.

PMID:
19948947
9.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.

Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, Farid NA, Ni L, Jakubowski JA, Salazar DE, Thieu VT, Payne CD.

Eur J Clin Pharmacol. 2010 Feb;66(2):127-35. doi: 10.1007/s00228-009-0737-1. Epub 2009 Nov 4.

PMID:
19888568
10.

Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.

Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T.

Xenobiotica. 2009 Nov;39(11):836-43. doi: 10.3109/00498250903191427.

PMID:
19845434
11.

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.

Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.

PMID:
19812348
12.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

Small DS, Wrishko RE, Ernest CS 2nd, Ni L, Winters KJ, Farid NA, Li YG, Brandt JT, Salazar DE, Borel AG, Kles KA, Payne CD.

J Clin Pharm Ther. 2009 Oct;34(5):585-94. doi: 10.1111/j.1365-2710.2009.01068.x.

PMID:
19744014
13.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Winters KJ, Salazar DE, Payne CD.

J Clin Pharm Ther. 2009 Oct;34(5):575-83. doi: 10.1111/j.1365-2710.2009.01067.x.

PMID:
19744013
14.

Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.

Small DS, Wrishko RE, Ernest CS 2nd, Ni L, Winters KJ, Farid NA, Li YG, Salazar DE, Payne CD.

Drugs Aging. 2009;26(9):781-90. doi: 10.2165/11315780-000000000-00000.

PMID:
19728751
15.

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2009 Nov;37(11):2145-52. doi: 10.1124/dmd.109.028498. Epub 2009 Aug 24.

PMID:
19704027
16.

Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.

Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS 2nd, Rohatagi S, Farid NA, Jakubowski JA, Winters KJ.

Platelets. 2009 Aug;20(5):316-27. doi: 10.1080/09537100903046317.

PMID:
19637095
17.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

Farid NA, Jakubowski JA, Payne CD, Li YG, Jin Y, Ernest II CS, Winters KJ, Brandt JT, Salazar DE, Small DS.

Curr Med Res Opin. 2009 Aug;25(8):1821-9. doi: 10.1185/03007990903018360.

PMID:
19530977
18.

Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.

Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, Kurihara A, Okazaki O, Farid NA, Ikeda T.

Xenobiotica. 2009 Mar;39(3):218-26. doi: 10.1080/00498250802650077.

PMID:
19280520
19.

Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.

Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T.

Drug Metab Pharmacokinet. 2008;23(6):412-20.

20.

Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.

Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, Ikeda T.

Drug Metab Dispos. 2009 Mar;37(3):589-93. doi: 10.1124/dmd.108.022988. Epub 2008 Dec 1.

PMID:
19047469
21.

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.

Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ.

Pharmacotherapy. 2008 Dec;28(12):1483-94. doi: 10.1592/phco.28.12.1483.

PMID:
19025429
22.

Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.

Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A.

J Pharm Biomed Anal. 2008 Dec 1;48(4):1219-24. doi: 10.1016/j.jpba.2008.08.020. Epub 2008 Aug 23.

PMID:
18829199
23.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Payne CD, Salazar DE, Winters KJ.

Curr Med Res Opin. 2008 Aug;24(8):2251-7. doi: 10.1185/03007990802205985.

PMID:
18786302
24.

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.

Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ.

Platelets. 2008 Jun;19(4):275-81. doi: 10.1080/09537100801891640.

PMID:
18569863
25.

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA.

Drug Metab Dispos. 2008 Jul;36(7):1227-32. doi: 10.1124/dmd.107.020248. Epub 2008 Mar 27.

PMID:
18372401
26.

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ.

J Clin Pharmacol. 2008 Apr;48(4):475-84. doi: 10.1177/0091270008315310. Epub 2008 Feb 26.

PMID:
18303127
27.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575.

PMID:
18278193
28.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555.

PMID:
18217157
29.

Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.

Farid NA, Payne CD, Ernest CS 2nd, Li YG, Winters KJ, Salazar DE, Small DS.

J Clin Pharmacol. 2008 Jan;48(1):53-9.

PMID:
18094219
30.

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.

Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.

J Cardiovasc Pharmacol. 2007 Nov;50(5):555-62.

PMID:
18030066
31.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ.

J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26.

32.

Disposition and metabolic fate of prasugrel in mice, rats, and dogs.

Smith RL, Gillespie TA, Rash TJ, Kurihara A, Farid NA.

Xenobiotica. 2007 Aug;37(8):884-901.

PMID:
17701835
33.

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.

Weerakkody GJ, Jakubowski JA, Brandt JT, Farid NA, Payne CD, Zhu J, Warner MR, Naganuma H, Winters KJ.

Am J Cardiol. 2007 Jul 15;100(2):331-6. Epub 2007 May 25.

PMID:
17631093
34.

Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats.

Hagihara K, Kurihara A, Kawai K, Kazui M, Takahashi M, Kawabata K, Farid NA, Ikeda T.

Xenobiotica. 2007 Jul;37(7):788-801.

PMID:
17620223
35.

Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.

Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, Naganuma H, Lachno DR, Winters KJ.

J Cardiovasc Pharmacol. 2007 Mar;49(3):167-73.

PMID:
17414229
36.

The disposition of prasugrel, a novel thienopyridine, in humans.

Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ.

Drug Metab Dispos. 2007 Jul;35(7):1096-104. Epub 2007 Apr 2.

PMID:
17403916
37.

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.

Clin Pharmacol Ther. 2007 May;81(5):735-41. Epub 2007 Mar 14.

PMID:
17361128
38.

Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.

Wickremsinhe ER, Tian Y, Ruterbories KJ, Verburg EM, Weerakkody GJ, Kurihara A, Farid NA.

Drug Metab Dispos. 2007 Jun;35(6):917-21. Epub 2007 Mar 12.

PMID:
17353347
39.

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ.

Am Heart J. 2007 Jan;153(1):66.e9-16.

PMID:
17174640
40.

Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.

Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H.

Rapid Commun Mass Spectrom. 2007;21(2):169-79.

PMID:
17154350
41.

The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.

Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, Winters KJ.

J Cardiovasc Pharmacol. 2006 Mar;47(3):377-84.

PMID:
16633079
42.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ.

Drug Metab Dispos. 2006 Apr;34(4):600-7. Epub 2006 Jan 13.

PMID:
16415119
43.

Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.

Perkins EJ, Cramer JW, Farid NA, Gadberry MG, Jackson DA, Mattiuz EL, O'Bannon DD, Weiss HJ, Wheeler WJ, Wood PG, Cassidy KC.

Drug Metab Dispos. 2003 Nov;31(11):1382-90.

PMID:
14570771
44.

Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog.

Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, Farid NA.

Xenobiotica. 2002 Nov;32(11):1045-52.

PMID:
12487733
45.

Confidence interval criteria for assessment of dose proportionality.

Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST.

Pharm Res. 2000 Oct;17(10):1278-83.

PMID:
11145235
46.

Salt form selection and characterization of LY333531 mesylate monohydrate.

Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL.

Int J Pharm. 2000 Apr 5;198(2):239-47.

PMID:
10767572
48.

Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs.

Farid NA, Schreiner KM, Coleman NL, Van Lier RB, Wrighton SA.

Drug Metab Dispos. 1996 Oct;24(10):1162-5.

PMID:
8894520
49.

Liquid chromatographic control of the identity, purity and "potency" of biomolecules used as drugs.

Farid NA, Atkins LM, Becker GW, Dinner A, Heiney RE, Miner DJ, Riggin RM.

J Pharm Biomed Anal. 1989;7(2):185-8. Review.

PMID:
2488619
50.

Clinical pharmacology and pharmacokinetics of fluoxetine: a review.

Bergstrom RF, Lemberger L, Farid NA, Wolen RL.

Br J Psychiatry Suppl. 1988 Sep;(3):47-50. Review. No abstract available.

PMID:
3074865

Supplemental Content

Loading ...
Support Center